Sales & Marketing

Pharm Exec speaks to Physicians Interactive CEO Donald Tramuto to understand about the key trends shaping the future of e-health.

By implementing integrated content compliance and digital asset management solutions into marketing workflows, life sciences companies can maximize the time and resources, writes David Bennett.

Jenna Earl outlines the three most important things to understand about portfolio positioning in pharma.

The age of genomics is giving rise to highly specialized diagnostic tools, targeted therapies, and personalized drug monitoring. This new generation of individualized treatments will require life sciences companies to evolve how they reach and educate the healthcare community. Are your commercial operations up to the task?

Measurement is a given in the pharmaceutical industry: dosage charts, chemistry formulas, budgets for testing, and budgets to go to market. When it comes to marketing, particularly through social media channels, measurement of return on investment (ROI) poses its own set of challenges. 

Commercial success for pharma brands now demands proactive strategies and interventions

In the white heat of a major brand launch, we can be consumed by the day to day challenges and make mistakes. But some of the worst mistakes can be avoided with a little foresight, writes Ken Begasse.

We are now living in a world of underdog brands. Unless you're first-to-market with a truly novel compound, a clear path to market access and solid reimbursement, then winning without a differentiated marketing strategy is simply not possible, writes Bill Drummy.

The biosimilars market forecaster must create a framework that captures the dynamics that operate in these markets and do justice to the uncertainty and quantification of assumptions, writes Arthur G. Cook

What you should know about integrated delivery networks.

Whether a brand is preparing to launch a new product, or taking a reinvigorated one back to market, it is widely accepted that those who form the emotional connection with customers are most likely to succeed.

Cures and therapies with curative intent are here in hepatitis C and are coming in other serious diseases. So everyone, from pharma suppliers patients, is scrambling to figure out what this means, writes Mike Rutstein.

Pharm Exec’s 9th annual Brand of the Year selection is Gilead Science’s back-to-back cures for HCV. We profile how both drugs reversed expectations around the listless product launch and revived industry reputation for startling breakthrough innovations.

Meike Wenzel and Clifford Hall examine a new concept for early commercialization planning to facilitate good cross-functional working practice.

Inspired by TV’s Mad Men, Julian Upton puts himself into a 1960 executive’s shoes to describe the “ethical pharma” industry of half a century ago

Neuroscience luminaries clamored onto the stage at this week's World Medical Innovation Forum in Boston to present the meeting’s much-anticipated "Disruptive Dozen".

Neil Gleghorn, looks at the upsurge of technology and metric-driven marketing operations in the strictly regulated pharmaceutical industries.

Advertorial: Ashfield Commercial & Medical Services believes that Pharma can use social media to play an important role in educating the healthcare professional (HCP) and the patient

FDA is under pressure to moderate oversight of pharma advertising and promotion, writes Jill Wechsler.

PharmExec talks to babylon founder and CEO Ali Parsa on how technology will deliver healthcare services to patients globally.

The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric - combined. It's counterintuitive…if not overwhelming, writes Lisa Barbadora

A new PwC survey reveals a strong need to fully embrace alternative commercial methods-not in a blind frenzy but through careful evaluation of which new sales strategies have true innovative potential.

Breaking down the four steps to a successful drug launch, using Keryx Biopharmaceuticals’ model for Auryxia, its new treatment for chronic kidney disease.

The interesting dynamic of industry-targeted memes in social media-still a quiet treading ground for pharmas.

As more new products vie for payer and prescriber attention, the stakes around launch success are higher than ever. Here are key traps to avoid in getting things right-when it really counts.

How pharma companies can catch up to the requirements of the modern marketing model.

New ways for pharma to make sure its sales reps stay sharp amid a flood of new information and a more complex selling climate.

By rethinking the role of the sales rep and the new skills it demands, pharma companies can put themselves in a prime competitive position.

The rush to digital will continue at a fast clip, but marketers need to reacquaint themselves with their brands' audiences.

What is and what should be keeping you up at night.